Category Archives: Telapravir v. Boceprevir Schering Plough Hep C Phase II

Meanwhile, Vertex’s Hep C Drug Candidate, Telapravir, keeps rollin’ toward FDA Approvability. . . .

Regular readers will remember that Vertex has taken a commanding lead in the race with Schering — to bring the next generation of Hep C drugs to market in the United States. This news, this morning, extends that lead. A Phase IIa trial, conducted by Vertex, has shown strong interim results.

When it rains, lately, in New Jersey — in Kenilworth — it pours.